LQDA Trading Analysis - 10/23/2026 04:17 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge of Liquidia Corp (LQDA) and are provided as contextual background only, separate from the data-driven analysis below.

• FDA approval of Yutrepia (treprostinil) for PAH and PH-ILD in 2025 expanded LQDA's commercial footprint versus competitor United Therapeutics.
• Recent patent litigation settlement with United Therapeutics reduced overhang and clarified U.S. market exclusivity timeline.
• Q2 2026 earnings (reported ~Aug 2026) showed rising Yutrepia net sales but continued operating losses typical of commercial-stage biopharma.
• Potential near-term catalyst: payer formulary additions and guidance updates at upcoming investor conferences.
• Context: Positive fundamental narrative aligns with bullish options sentiment below, though the embedded price history shows a sharp Sept 30 crash (low $30.17) and volatile recovery.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data (source: FinWin fundamentals, local):

• Trailing P/E: 23.20; Trailing EPS: $1.57; Market Cap: $3.82B; Shares Outstanding: 89.51M.
• Dividend Yield: 0.00% (no dividend). Beta: 1.15 (moderate market sensitivity).
• 52-Week Range: $21.94 (low) to $93.61 (high) — current price near middle-lower band of annual range.
• Institutional Ownership: 43.01% — moderate institutional presence.
• Average Volume: 7.12M; Historical Volatility: 264.70% (extremely high).
• PEG Ratio, Forward P/E, Revenue Growth, Profit Margins, ROE, Debt/Equity, Free Cash Flow: all null/not provided — cannot assess profitability trends or leverage.
• Analyst consensus and target mean price: null (no embedded analyst data).
• Alignment: Fundamentals show a profitable-on-paper EPS (P/E 23.2) but lack of margin/cash-flow data diverges from the technical picture of a post-crash recovery with RSI overbought at 77.24.

Current Market Position

From embedded daily and minute data: Daily close on 2026-10-22 was $39.47 (open $38.75, high $40.08, low $38.22, volume 2.55M). Minute bars show 2026-10-22 09:30 open $38.75 climbing to $39.11 by 09:50; by 2026-10-23 15:50 last bar close $42.72 (open $42.31, high $42.74, low $42.31, volume 115,634) — intraday upward momentum across the two sessions.

Key observational levels from data: Recent daily low zone $38.22 (10-22) and high $40.08; 30-day range low $22.31, high $74.74. Minute-bar late-session support near $42.31, resistance near $42.74.

Technical Analysis

SMA trends: Price ($39.47) > SMA 5 ($36.60) > SMA 20 ($37.06) but below SMA 50 ($56.53) — short-term bullish alignment, longer-term bearish. No golden cross (SMA 5/20 below SMA 50). RSI 77.24 indicates overbought momentum. MACD (-6.67) below signal (-5.34), histogram -1.33 = bearish momentum divergence vs price. Bollinger: price above middle ($37.06), far below upper ($66.83) = expansion room. 30-day range: price at $39.47 is ~31% up from low, ~47% below high.

True Sentiment Analysis (Delta 40-60 Options)

From LQDA_options_20261023 data: Sentiment Bullish. Call dollar volume $1,394,040 (85.2%) vs Put $241,490 (14.8%); 2,059 call contracts vs 183 puts; 28 call trades vs 7 put trades. Total analyzed $1,635,530.

Conviction: Heavy call-side directional positioning (Delta 40-60 filtered) shows strong near-term upside expectation. Divergence: Technicals show MACD bearish and SMA 50 resistance, while options flow is bullish — matches spread engine note: "Divergence detected between technical indicators and options sentiment."

Options flow is the only sentiment source; no live X posts retrieved.

Key Price Levels (Observational Only)